Transaction #4680 · Form 4 · 0001567160-25-000008
NEUROCRINE BIOSCIENCES INC · Exercise / conversion · Common Stock
NEUROCRINE BIOSCIENCES INC · Transacted November 1, 2025 · Filed November 4, 2025
What does this filing report?
An SEC Form 4 filing for NEUROCRINE BIOSCIENCES INC records an exercise / conversion involving Common Stock on November 1, 2025. The reported quantity was 613. The filing date is November 4, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- NEUROCRINE BIOSCIENCES INC
- Company CIK
- 0000914475
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 613
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 140,720
- Ownership description
- Not reported
- SEC acceptance time
- Nov 4, 2025, 8:18 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Gano Kyle ↗
Chief Executive Officer · Director
CIK 0001567160
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Includes an aggregate of 200 shares purchased on February 28, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
- F2
- The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- F3
- Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- F4
- This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, and will vest as to 614 shares on November 1, 2026, 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.